Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Item
http://www.wikidata.org/entity/Q34158739
Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical PracticeBone turnover and bone mineral density in HIV-1 infected Chinese taking highly active antiretroviral therapy -a prospective observational study.Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trialThe RADAR study: week 48 safety and efficacy of RAltegravir combined with boosted DARunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naive patients. Impact on bone healthDairy calcium intake and lifestyle risk factors for bone loss in hiv-infected and uninfected Mediterranean subjects.Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice.Increased bone resorption during tenofovir plus lopinavir/ritonavir therapy in Chinese individuals with HIVThe ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavirRole of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection.HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.Different Impact Of Antiretroviral Drugs On Bone Differentiation In An In Vitro Model.Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.An increased risk for fractures: another cause of frailty in HIV-infected subjects.Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection.Mexican patients with HIV have a high prevalence of vertebral fractures.Continued Interest and Controversy: Vitamin D in HIV.
P2860

Prospective evaluation of bone markers, parathormone and 1,25-(OH)₂ vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz.

Item
http://www.wikidata.org/entity/Q34158739
description
2012 nî lūn-bûn
@nan
2012 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@ast
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@en
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@nl
type
label
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@ast
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@en
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@nl
prefLabel
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@ast
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@en
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@nl
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932
P356
P1433
P1476
Prospective evaluation of bone ...... anavir/ritonavir or efavirenz.
@en
P2093
P2860
P2888
P304
P31
P356
P478
P50
P577
P5875
P6179
P698
P921
P932